Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) FCF Margin: 2021-2024

Historic FCF Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to 6.00%.

  • Kiniksa Pharmaceuticals International's FCF Margin rose 2030.00% to 18.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.03%, marking a year-over-year increase of 1417.00%. This contributed to the annual value of 6.00% for FY2024, which is 113.00% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported FCF Margin of 6.00% as of FY2024, which was up 23.20% from 4.87% recorded in FY2023.
  • Kiniksa Pharmaceuticals International's FCF Margin's 5-year high stood at 57.02% during FY2022, with a 5-year trough of -328.75% in FY2021.
  • Moreover, its 3-year median value for FCF Margin was 6.00% (2024), whereas its average is 22.63%.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's FCF Margin surged by 38,577bps in 2022, and later slumped by 5,215bps in 2023.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's FCF Margin (Yearly) stood at -328.75% in 2021, then spiked by 38,577bps to 57.02% in 2022, then plummeted by 5,215bps to 4.87% in 2023, then soared by 113bps to 6.00% in 2024.